Tyra Biosciences (TYRA) EPS (Weighted Average and Diluted) (2021 - 2026)
Tyra Biosciences (TYRA) reported EPS (Weighted Average and Diluted) of -$0.64 for Q1 2026, down 36.17% on a YoY basis from -$1.0 in Q1 2025, and down 14.29% quarter-over-quarter from -$0.56 in Q4 2025.
Tyra Biosciences (TYRA) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Tyra Biosciences has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at -$0.64 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 36.17% year-over-year to -$0.64; the trailing twelve-month figure through Mar 2026 stood at -$2.17 (down 33.13% YoY), and the FY2025 full-year result was -$2.01, down 33.11% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.64, down from -$0.56 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.28 in Q1 2023, with the low at -$0.64 in Q1 2026.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.42 across 5 years, with a median of -$0.41 in 2024.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 85.19% in 2022 against a maximum downside of 117.44% in 2022.
- Tyra Biosciences' EPS (Weighted Average and Diluted) stood at -$0.3 in 2022, then plunged by 76.67% to -$0.53 in 2023, then increased by 18.87% to -$0.43 in 2024, then plunged by 30.23% to -$0.56 in 2025, then declined by 14.29% to -$0.64 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.64 (Q1 2026), -$0.56 (Q4 2025), and -$0.5 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 0.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -0.61 |
| 10 | Tyra Biosciences | 1.67 Bn | 1.67 Bn | - | -0.64 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.64 |
| Dec 31, 2025 | -0.56 |
| Sep 30, 2025 | -0.50 |
| Jun 30, 2025 | -0.47 |
| Mar 31, 2025 | -0.47 |
| Dec 31, 2024 | -0.43 |
| Sep 30, 2024 | -0.41 |
| Jun 30, 2024 | -0.32 |
| Mar 31, 2024 | -0.35 |
| Dec 31, 2023 | -0.53 |
| Sep 30, 2023 | -0.49 |
| Jun 30, 2023 | -0.31 |
| Mar 31, 2023 | -0.28 |
| Dec 31, 2022 | -0.30 |
| Sep 30, 2022 | -0.30 |
| Jun 30, 2022 | -0.36 |
| Mar 31, 2022 | -0.36 |
| Dec 31, 2021 | 1.72 |
| Sep 30, 2021 | -0.72 |
| Jun 30, 2021 | -2.43 |